Loading company…
RootPath provides synthetic biology and gene cell therapy development services.
RootPath develops synthetic biology and gene cell therapy technologies. Its platform supports DNA assembly and gene library customization, and it provides vectors including pUC19, pET, and pcDNA for inserted genes from 450 bp to 10 kb. Founded in 2024, the company is based in Chengdu, China. In April 2025, it raised venture funding led by YuanBio Venture, with participation from Geuniom Group and Sichuan Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in